Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 1;8(5):e2511825.
doi: 10.1001/jamanetworkopen.2025.11825.

Weight Loss in Midlife, Chronic Disease Incidence, and All-Cause Mortality During Extended Follow-Up

Timo E Strandberg  1   2   3 , Arto Y Strandberg  1   2 , Satu Jyväkorpi  1   2 , Annele Urtamo  1   2 , Solja T Nyberg  4   5 , Philipp Frank  6 , Jaana Pentti  4   5   7   8 , Kaisu H Pitkälä  1   2 , Mika Kivimäki  4   5   6
Affiliations

Weight Loss in Midlife, Chronic Disease Incidence, and All-Cause Mortality During Extended Follow-Up

Timo E Strandberg et al. JAMA Netw Open. .

Abstract

Importance: Few studies have examined long-term health benefits among individuals with sustained weight loss beyond its association with decreased diabetes risk.

Objective: To examine the long-term association of body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) changes during healthy midlife (ages 40-50 years) with later-life morbidity and mortality.

Design, setting, and participants: This cohort study analyzed data from 3 cohorts that included repeated height and weight measurements: the Whitehall II study (WHII; baseline, 1985-1988), Helsinki Businessmen Study (HBS; baseline, 1964-1973), and Finnish Public Sector study (FPS; baseline, 2000). Participants were categorized into 4 groups based on their first 2 weight assessments and followed up for morbidity and mortality outcomes. Data analyses were conducted between February 11, 2024, and February 20, 2025.

Exposures: Midlife BMI change was categorized as persistent BMI less than 25, BMI change from 25 or greater to less than 25, BMI change from less than 25 to 25 or greater, and persistent BMI of 25 or greater.

Main outcomes and measures: Incident chronic disease, including type 2 diabetes, myocardial infarction, stroke, cancer, asthma, or chronic obstructive pulmonary disease, was assessed in WHII and FPS, and all-cause mortality was assessed in HBS. These outcomes were obtained from linked electronic health records in national health registries.

Results: There were 23 149 participants, including 4118 men and women (median [IQR] age at first visit, 39 [37-42] years; 2968 men [72.1%]) from WHII, 2335 men (median [IQR] age at first visit, 42 [38-45] years) from HBS, and 16 696 men and women (median [IQR] age at first visit, 39 [34-43] years; 13 785 women [82.6%]) from FPS. During a median (IQR) follow-up of 22.8 (16.9-23.3) years, after adjusting for smoking, systolic blood pressure, and serum cholesterol at the first evaluation, WHII participants with weight loss had a decreased risk of developing chronic disease (hazard ratio [HR], 0.52; 95% CI, 0.35-0.78) compared with participants with persistent overweight. This finding was replicated after excluding diabetes from the outcome (HR, 0.58; 95% CI, 0.37-0.90). The corresponding HR in FPS was 0.43 (95% CI, 0.29-0.66) over a median (IQR) follow-up of 12.2 (8.2-12.2) years. In HBS, weight loss was associated with decreased mortality (HR, 0.81; 95% CI, 0.68-0.96) during an extended follow-up (median [IQR], 35 [24-43] years).

Conclusions and relevance: In this study, conducted when surgical and pharmacological weight-loss interventions were nearly nonexistent, sustained midlife weight loss compared with persistent overweight was associated with a decreased risk of chronic diseases beyond type 2 diabetes and decreased all-cause mortality.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr T. E. Strandberg reported receiving grants from the Sohlberg Foundation during the conduct of the study and personal fees from pharmaceutical companies outside the submitted work and serving as a member of the National Obesity Guidelines group. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Selection of Study Participants
Participant selection is shown for the Whitehall II study, Helsinki Businessmen Study (HBS), and Finnish Public Sector (FPS) study. BMI indicates body mass index.
Figure 2.
Figure 2.. Cumulative Hazard of Incident Chronic Disease and Mortality in Primary Analysis
HBS indicates Helsinki Businessmen Study.
See this image and copyright information in PMC

References

    1. Cleto AS, Schirlo JM, Beltrame M, et al. . Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis. Int J Obes (Lond). 2025;49(1):21-30. doi:10.1038/s41366-024-01646-9 - DOI - PubMed
    1. Syn NL, Cummings DE, Wang LZ, et al. . Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397(10287):1830-1841. doi:10.1016/S0140-6736(21)00591-2 - DOI - PubMed
    1. Pan XR, Li GW, Hu YH, et al. . Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20(4):537-544. doi:10.2337/diacare.20.4.537 - DOI - PubMed
    1. Tuomilehto J, Lindström J, Eriksson JG, et al. ; Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-1350. doi:10.1056/NEJM200105033441801 - DOI - PubMed
    1. Knowler WC, Barrett-Connor E, Fowler SE, et al. ; Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512 - DOI - PMC - PubMed

Publication types